NEW YORK (GenomeWeb News) – KineMed said today that it has received a $225,000 Phase I Small Business Innovation Research contract from the National Heart, Lung, and Blood Institute for research into biomarkers for the early detection of myocardial fibrosis.

The contract is focused specifically on developing non-invasive methods to detect and monitor myocardial fibrosis in vivo. In previous work, KineMed has identified via its Dynamic Proteomics technology blood proteins that may potentially serve as markers of the fibrotic process in remodeling heart tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.